Stock listing

Hamburg:SP4P Achieve Life Sciences, Inc. Aktie

German listing (Hamburg) of Achieve Life Sciences, Inc. · home listing NASDAQ:ACHV

Follow Achieve Life Sciences, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:ACHV

$5.87 USD -0.05 (-0.8%)

Close on Nov 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ACHV

Past year +49.3% · daily closes, Nov 19, 2025 – Nov 11, 2026, adjusted for splits
Day range
$5.61 – $5.99 USDNov 19, 2026
Volume
945,707 sharesNov 19, 2026
Market cap
$645.9M USDAt the close on Nov 19, 2026 · price × 110.0M shares outstanding
52-week range
$2.62 – $8.64 USDLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
Traded on an average day
$10.94M USDMedian day 1.33M shares · last 3 months, Aug 19, 2026 – Nov 11, 2026
Achieve Life Sciences, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ACHV · Home$5.87 USD-0.05 (-0.8%)945,707$5.92$5.99$5.61$5.92Delayed 15+ min · 9:30 AM EST, Nov 19, 2026
Frankfurt:SP4P€5.30 EUR-0.05 (-0.9%)—€5.30€5.30€5.30€5.35Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 19, 2026 – Nov 11, 2026 · NASDAQ:ACHV · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$6.45-0.33-4.9%$6.54$6.555$6.291,155,289
$6.78+0.06+0.9%$6.83$6.91$6.521,088,136
$6.72+0.345+5.4%$6.55$6.75$6.251,074,229
$6.375-0.605-8.7%$7.00$7.00$6.251,812,252
$6.98+0.25+3.7%$6.87$7.15$6.811,393,672
$6.73+0.12+1.8%$6.69$6.89$6.625895,322
$6.61-0.22-3.2%$6.89$6.89$6.331,531,845
$6.83-0.36-5.0%$7.12$7.27$6.571,376,391
$7.19+0.34+5.0%$6.90$7.23$6.901,374,471
$6.85-0.08-1.2%$6.85$6.97$6.68966,162
$6.93+0.39+6.0%$6.59$6.94$6.451,486,026
$6.54+0.05+0.8%$6.53$6.65$6.47701,504
$6.49-0.01-0.2%$6.48$6.61$6.36590,135
$6.50-0.01-0.2%$6.39$6.64$6.38963,299
$6.510.000.0%$6.50$6.67$6.382,467,797
$6.51-0.095-1.4%$6.58$6.935$6.472,098,040
$6.605+0.225+3.5%$6.54$6.735$6.455823,013
$6.38-0.59-8.5%$6.98$7.02$6.221,992,986
$6.97-0.03-0.4%$7.00$7.13$6.831,197,729
$7.000.000.0%$6.98$7.11$6.831,642,257
$7.00-0.06-0.8%$7.00$7.20$6.921,646,100
$7.06-0.35-4.7%$7.39$7.45$7.05948,700
$7.41+0.22+3.1%$7.20$7.48$7.14987,300
$7.19-0.05-0.7%$7.14$7.32$7.051,108,900
$7.24+0.21+3.0%$7.02$7.35$6.961,035,900
$7.03+0.02+0.3%$7.06$7.23$6.891,056,400
$7.01-0.23-3.2%$7.24$7.34$6.831,702,900
$7.24-0.29-3.9%$7.62$7.63$7.051,886,300
$7.53-0.56-6.9%$7.89$8.04$7.521,153,300
$8.09+0.40+5.2%$8.08$8.28$7.872,377,200
$7.69-0.06-0.8%$7.75$7.76$7.471,027,600
$7.75+0.21+2.8%$7.50$7.84$7.351,301,100
$7.54-0.29-3.7%$7.90$7.96$7.511,423,000
$7.830.000.0%$7.79$8.14$7.621,141,100
$7.83-0.29-3.6%$8.15$8.20$7.761,328,100
$8.12+0.07+0.9%$8.15$8.42$7.951,674,900
$8.05+0.07+0.9%$8.03$8.07$7.821,006,800
$7.98+0.07+0.9%$7.91$8.09$7.802,830,200
$7.91+0.49+6.6%$7.59$8.11$7.591,871,100
$7.42+0.10+1.4%$7.43$7.62$7.271,905,700
$7.32+0.09+1.2%$7.22$7.33$7.021,383,900
$7.23+0.17+2.4%$7.06$7.29$7.021,430,300
$7.06-0.22-3.0%$7.38$7.44$7.011,460,700
$7.28-0.26-3.4%$7.48$7.56$7.212,476,300
$7.54-0.30-3.8%$7.82$7.85$7.522,367,200
$7.84-0.65-7.7%$8.32$8.34$7.823,533,200
$8.49+0.18+2.2%$8.20$8.56$8.10886,400
$8.31-0.17-2.0%$8.49$8.64$8.211,532,400
$8.48+0.23+2.8%$8.27$8.52$8.251,044,200
$8.25+0.31+3.9%$7.83$8.40$7.831,652,200
$7.94-0.16-2.0%$8.07$8.14$7.821,059,000
$8.10-0.08-1.0%$8.17$8.22$7.95988,900
$8.18-0.09-1.1%$8.31$8.40$8.16987,700
$8.27+0.10+1.2%$8.20$8.34$8.021,322,200
$8.17+0.23+2.9%$8.04$8.42$8.011,322,400
$7.94-0.05-0.6%$7.99$8.12$7.68920,300
$7.99-0.03-0.4%$8.11$8.19$7.901,060,700
$8.02-0.51-6.0%$8.42$8.46$7.961,453,900
$8.53+1.01+13.4%$7.62$8.61$7.623,924,700

Splits

4 splits since 2008 · NASDAQ:ACHV · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
1-for-10Consolidation
1-for-11Consolidation
1-for-18Consolidation
Ticker
Hamburg:SP4P
Asset type
Stock
Exchange
Hamburg
Currency
EUR

What changed lately

Latest news

All Achieve Life Sciences, Inc. news

Achieve Life Sciences, Inc. on 6ix

News releases
27 in the last 12 months · 179 in all · newest Nov 9, 2026 · oldest 2019
Calls
25 calls with a replay · 25 with a transcript · latest May 12, 2026
Decks
13 decks · latest Nov 18, 2026

Where Achieve Life Sciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ACHV · Home listingNASDAQUnited StatesUSD
gettex:SP4PgettexGermanyEUR
Lang & Schwarz:A2QAR3Lang & SchwarzGermanyEUR
Munich:SP4PMunichGermanyEUR
BOATS:ACHVBOATSUnited StatesUSD
LS Exchange:A2QAR3LS ExchangeGermanyEUR
Tradegate:SP4PTradegateGermanyEUR
Frankfurt:SP4PFrankfurtGermanyEUR
Stuttgart:SP4PStuttgartGermanyEUR
Dusseldorf:SP4PDusseldorfGermanyEUR
Hamburg:SP4P · This pageHamburgGermanyEUR

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 19, 2026

Enterprise value
$458.4M USD
P/E
Loss
EV/sales
4,021×
EV/EBITDA
Negative EBITDA
Price/book
3.6×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.1×
Beta vs S&P 500
1.86

Forecasts

9 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
14.58 USD · Analysts' mean
EPS, year to Dec 2026
-1.34 · 4 analysts

Team and board

Officers

OfficerRole
Andrew D. GoldbergChief Executive Officer & Director
Benjamin HalladayChief Financial Officer
Erik AtkissonChief Legal Officer
Kaitlyn TusonSenior Vice President, Marketing and Communications
Nicole JonesVP, Strategic Communications and Stakeholder Relations
Mark RubinsteinChief Medical Officer

Board

DirectorRole
Lucian IancoviciChairman of the Board of Directors
Aaron E. RoystonDirector
Andrew D. GoldbergChief Executive Officer & Director
Christopher MartinDirector
Jeffrey FarrowDirector
Nancy PhelanDirector
Reid WaldmanDirector
Richard StewartDirector
Tom SelligDirector

Events

Calls

CallWhenStatus
Achieve Life Sciences (NASDAQ:ACHV) Q1 2026 Earnings CallTue, May 12, 2026 · 8:30 AM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q4 2025 Earnings CallTue, Mar 24, 2026 · 8:30 AM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q3 2025 Earnings CallThu, Nov 06, 2025 · 8:30 AM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q2 2025 Earnings CallThu, Aug 07, 2025 · 8:30 AM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q1 2025 Earnings CallTue, May 13, 2025 · 8:30 AM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q4 2024 Earnings CallTue, Mar 11, 2025 · 8:30 AM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q3 2024 Earnings CallThu, Nov 07, 2024 · 4:30 PM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q2 2024 Earnings CallTue, Aug 13, 2024 · 4:30 PM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q1 2024 Earnings CallThu, May 09, 2024 · 4:30 PM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q4 2023 Earnings CallThu, Mar 28, 2024 · 4:30 PM ETReplay
All 25 calls
CallWhenStatus
Achieve Life Sciences (NASDAQ:ACHV) Q3 2023 Earnings CallThu, Nov 09, 2023 · 4:30 PM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q2 2023 Earnings CallTue, Aug 15, 2023 · 8:30 AM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q1 2023 Earnings CallTue, May 09, 2023 · 4:30 PM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q4 2022 Earnings CallThu, Mar 16, 2023 · 4:30 PM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q3 2022 Earnings CallMon, Nov 14, 2022 · 4:30 PM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q2 2022 Earnings CallThu, Aug 11, 2022 · 4:30 PM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q1 2022 Earnings CallThu, May 12, 2022 · 4:30 PM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q4 2021 Earnings CallThu, Mar 10, 2022 · 4:30 PM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q3 2021 Earnings CallTue, Nov 09, 2021 · 4:30 PM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q2 2021 Earnings CallThu, Aug 12, 2021 · 4:30 PM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q1 2021 Earnings CallThu, May 13, 2021 · 4:30 PM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q4 2020 Earnings CallThu, Mar 11, 2021 · 4:30 PM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q3 2020 Earnings CallThu, Nov 12, 2020 · 4:30 PM ETReplay
Achieve Life Sciences (NASDAQ:ACHV) Q2 2020 Earnings CallFri, Aug 07, 2020Replay
Achieve Life Sciences (NASDAQ:ACHV) Q1 2020 Earnings CallThu, May 14, 2020Replay

Results days

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open−4.9%
Q2 2026Aug 11, 2026 · Before open+1.5%
Q1 2026May 12, 2026 · Before open+7.2%
Q4 2025Mar 12, 2026−4.8%
Q3 2025Nov 6, 2025 · Before open−3.9%
Q2 2025Aug 7, 2025 · Before open0.0%
Q1 2025May 13, 2025 · Before open+6.8%
Q4 2024Mar 26, 2025 · Before open+2.1%
Q3 2024Nov 7, 2024 · After close−7.4%
Q2 2024Aug 13, 2024 · After close+0.6%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close+1.8%
Q4 2023Mar 13, 2024 · Before open+1.6%
Q3 2023Nov 9, 2023 · After close−1.9%
Q2 2023Aug 14, 2023 · After close−3.0%
Q1 2023May 9, 2023 · After close+12.7%
Q4 2022Mar 16, 2023 · After close−2.0%
Q3 2022Nov 14, 2022 · After close+5.5%
Q2 2022Aug 11, 2022 · After close−3.9%
Q1 2022May 12, 2022 · After close+3.9%
Q4 2021Mar 10, 2022 · Before open−1.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (2026)Investor deck30 slidesNov 18, 2026
Investor Presentation (July 2026)Investor deck25 slidesJuly 2026
Q2 2025 Earnings PresentationEarnings24 slidesAug 7, 2025
Technical Presentation (May 2023)Technical24 slidesMay 23, 2023
Technical Presentation (April 2022)Technical11 slidesApr 27, 2022
IPO Roadshow (November 2020)IPO roadshow32 slidesNov 30, 2020
IPO Roadshow (December 2019)IPO roadshow39 slidesDec 2, 2019
Technical Presentation (September 2019)Technical38 slidesSep 13, 2019
IPO Roadshow (June 2018)IPO roadshow36 slidesJun 6, 2018
Corporate Update (February 2018)Corporate update11 slidesFeb 20, 2018
All 13 decks
DeckKindSlidesDate
Oncogenex Pharmaceuticals — Merger or Acquisition (June 2017)Merger or acquisition33 slidesJun 13, 2017
Oncogenex Pharmaceuticals — Merger or Acquisition (January 2017)Merger or acquisition26 slidesJan 6, 2017
OncoGenex Pharmaceuticals — FY2008 Earnings PresentationEarnings26 slidesMar 11, 2009

Open Decks

Financings

RaiseDate
Private placement of securities and milestone warrants
Update: US$180M–US$354M
Use of proceeds: Development and launch of cytisinicline, if approved, for nicotine dependence
Apr 16, 2026
Public offering of common stock and accompanying common warrants
Closed: US$45M raised · US$3 a share · Warrants at US$3 for 60 months · Citizens Capital Markets +2
Dealers: Citizens Capital Markets (co-lead), Raymond James (co-lead), Lake Street Capital Markets, LLC
Use of proceeds: Advance cytisinicline through potential FDA marketing approval, plus working capital and general corporate purposes
Jun 30, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000005.06M
Cost of revenue228.0K229.0K228.0K236.0K250.0K255.0K254.0K282.0K282.0K0
Gross profit-228.0K-229.0K-228.0K-236.0K-250.0K-255.0K-254.0K-282.0K-282.0K5.06M
Research and development23.0M22.8M15.8M30.1M24.0M6.88M9.67M5.87M3.10M286.0K
Selling, general and administrative31.9M16.3M11.4M10.7M9.13M7.87M6.85M6.95M3.53M8.93M
Operating income-54.9M-39.1M-27.3M-40.8M-33.1M-14.8M-16.5M-12.8M-6.63M-21.2M
Depreciation and amortization228.0K229.0K228.0K236.0K250.0K255.0K31.0K60.0K59.0K188.0K
EBITDA-54.7M-38.8M-27.0M-40.6M-32.8M-14.5M-16.5M-12.8M-6.57M-21.0M
Interest expense819.0K2.18M2.85M1.79M17.0K69.0K0000
Income before tax-54.6M-39.8M-29.8M-42.4M-33.2M-14.7M-16.4M-12.7M-13.6M-1.74M
Income tax-39.8M-475.0K-250.0K-69.0K-254.0K-126.0K-3.05M0
Net income-54.6M-39.8M-29.8M-42.4M-33.2M-14.7M-16.4M-12.7M-10.6M-1.23M
Earnings per share, basic-1.25-1.24-1.50-4.00-4.08-5.42-39.76-72.29-22.07-581.25
Earnings per share, diluted-1.25-1.24-1.50-4.00-4.08-5.42-39.76-72.29-22.07-581.25

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents20.9M12.8M15.5M24.8M43.0M35.9M16.7M9.52M5.28M15.0K
Short-term investments15.5M21.6M050.0K5.09M222.0K10.2M
Receivables111.0K105.0K153.0K8.00K7.00K9.00K478.0K
Inventory-2.49M-8.00K-50.0K222.0K0
Current assets39.9M36.5M17.0M27.3M44.6M37.0M17.3M15.5M5.91M18.0K
Property, plant and equipment3.00K8.00K13.0K4.00K15.0K42.0K57.0K35.0K59.0K258.0K
Goodwill1.03M1.03M1.03M1.03M1.03M1.03M1.03M1.03M1.03M1.03M
Total assets41.8M38.6M19.4M30.0M47.5M40.3M21.1M19.1M9.89M3.81M
Accounts payable867.0K1.95M618.0K1.66M841.0K332.0K859.0K144.0K213.0K95.0K
Current liabilities9.08M6.68M20.8M21.6M4.55M2.94M2.87M3.27M2.01M3.07M
Long-term debt11.2M9.84M16.1M14.9M049.0K
Total debt15.0M9.96M16.7M16.2M15.0M169.0K362.0K35.0K27.0K106.0K
Total liabilities20.3M17.7M20.8M21.7M19.5M3.01M3.03M3.28M2.01M3.20M
Shareholders' equity21.5M20.9M-1.45M8.30M28.0M37.3M18.1M15.8M15.8M610.0K
Shares outstanding53.2M34.7M21.2M17.9M9.45M6.11M1.47M6.72M1.19M21.2K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-49.5M-29.8M-24.5M-37.6M-29.4M-13.5M-15.2M-10.6M-9.11M-202.0K
Capital spending-3.00K0-21.0K0-17.0K-17.0K-53.0K-46.0K-46.0K-46.0K
Free cash flow-49.5M-29.8M-24.5M-37.6M-29.4M-13.5M-15.3M-10.7M-9.11M-248.0K
Cash from investing6.11M-21.6M-21.0K-17.0K-17.0K5.04M-5.13M12.6M10.6M
Cash from financing51.5M48.5M15.3M19.3M36.6M32.7M17.3M19.8M2.00M150.0K
Dividends paid00
Share buybacks00-30.0K-4732.7M4.99M14.8M-50
Change in cash8.18M-2.82M-9.22M-18.3M7.17M19.2M7.15M4.01M5.54M-52.0K

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 6, 2026Insider tradeSEC
8-K · Current reportOct 1, 2026Management or board changeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeAug 17, 2026Big-stake noticeSEC
8-K · Current reportAug 14, 2026Current reportSEC
424B5 · ProspectusAug 14, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 28, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 27, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 8, 2026Big-stake noticeSEC
8-K · Current reportJul 6, 2026Meeting outcomeSEC
ARS · Annual report to shareholdersJun 8, 2026Annual reportSEC
DEF 14A · Proxy statementJun 8, 2026Meeting noticeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 2, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 2, 2026Insider tradeSEC
8-K · Current reportJun 2, 2026Management or board changeSEC
PRE 14A · Preliminary proxy statementMay 29, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveMay 22, 2026Other filingsSEC
CORRESP · Letter to the SECMay 19, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 18, 2026Other filingsSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 13, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMay 12, 2026Offer documentSEC
S-3 · Registration statementMay 12, 2026Offer documentSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 7, 2026Big-stake noticeSEC
10-K/A · Annual report, amendedApr 30, 2026Annual reportSEC
SCHEDULE 13D · Big-stake noticeApr 27, 2026Big-stake noticeSEC
3 · Initial statement of ownershipApr 27, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 24, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeApr 24, 2026Big-stake noticeSEC
3 · Initial statement of ownershipApr 24, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 24, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 24, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 24, 2026Big-stake noticeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 21, 2026Insider tradeSEC
8-K · Current reportApr 16, 2026Material contractSEC
S-8 · Registration statement for employee plansApr 16, 2026Offer documentSEC
S-8 · Registration statement for employee plansMar 24, 2026Offer documentSEC
10-K · Annual reportMar 24, 2026Annual reportSEC
8-K · Current reportMar 24, 2026ResultsSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveJan 30, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 29, 2026Big-stake noticeSEC
CORRESP · Letter to the SECJan 27, 2026Other filingsSEC
UPLOAD · Letter from the SECJan 27, 2026Other filingsSEC
S-3 · Registration statementJan 23, 2026Offer documentSEC
3 · Initial statement of ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
3 · Initial statement of ownershipOct 21, 2025Insider tradeSEC
8-K · Current reportOct 7, 2025Management or board changeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 19, 2025Insider tradeSEC
8-K · Current reportSep 11, 2025Management or board changeSEC
4 · Change in ownershipSep 8, 2025Insider tradeSEC
4 · Change in ownershipSep 8, 2025Insider tradeSEC
4 · Change in ownershipSep 8, 2025Insider tradeSEC
4 · Change in ownershipSep 8, 2025Insider tradeSEC
4 · Change in ownershipSep 8, 2025Insider tradeSEC
4 · Change in ownershipSep 8, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 5, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
8-K · Current reportJun 27, 2025Material contractSEC
424B5 · ProspectusJun 27, 2025Offer documentSEC
424B5 · ProspectusJun 26, 2025Offer documentSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
8-K · Current reportJun 6, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 9, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 30, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 28, 2025Annual reportSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
4 · Change in ownershipMar 19, 2025Insider tradeSEC
4 · Change in ownershipMar 19, 2025Insider tradeSEC
10-K · Annual reportMar 11, 2025Annual reportSEC
8-K · Current reportMar 11, 2025ResultsSEC
8-K · Current reportFeb 10, 2025Current reportSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 14, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 14, 2025Insider tradeSEC
S-8 · Registration statement for employee plansJan 10, 2025Offer documentSEC
8-K · Current reportJan 10, 2025Management or board changeSEC
4 · Change in ownershipDec 9, 2024Insider tradeSEC
4 · Change in ownershipDec 9, 2024Insider tradeSEC
3 · Initial statement of ownershipDec 9, 2024Insider tradeSEC
8-K · Current reportDec 9, 2024Management or board changeSEC
S-8 · Registration statement for employee plansDec 5, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 19, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveNov 15, 2024Other filingsSEC
CORRESP · Letter to the SECNov 14, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 14, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
S-3 · Registration statementNov 7, 2024Offer documentSEC
POS AM · Amendment to an effective registrationNov 7, 2024Offer documentSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SC 13G · Big-stake noticeNov 4, 2024Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 31, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 25, 2024Big-stake noticeSEC
3 · Initial statement of ownershipOct 25, 2024Insider tradeSEC
8-K · Current reportSep 27, 2024Material contractSEC
424B5 · ProspectusSep 27, 2024Offer documentSEC
8-K · Current reportAug 26, 2024Management or board changeSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 13, 2024ResultsSEC
8-K · Current reportJul 29, 2024Material contractSEC
EFFECT · Notice that a registration is effectiveJul 9, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 3, 2024Other filingsSEC
CORRESP · Letter to the SECJul 3, 2024Other filingsSEC
S-3 · Registration statementJun 28, 2024Offer documentSEC
8-K · Current reportJun 27, 2024Current reportSEC
8-K · Current reportJun 6, 2024Meeting outcomeSEC
SC 13G/A · Big-stake notice, amendedMay 20, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeMay 17, 2024Big-stake noticeSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
EFFECT · Notice that a registration is effectiveMay 7, 2024Other filingsSEC
CORRESP · Letter to the SECMay 2, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 2, 2024Other filingsSEC
S-3 · Registration statementApr 26, 2024Offer documentSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
4 · Change in ownershipApr 23, 2024Insider tradeSEC
4 · Change in ownershipApr 23, 2024Insider tradeSEC
4 · Change in ownershipApr 23, 2024Insider tradeSEC
4 · Change in ownershipApr 23, 2024Insider tradeSEC
S-8 · Registration statement for employee plansMar 28, 2024Offer documentSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
8-K · Current reportMar 28, 2024ResultsSEC
SC 13G · Big-stake noticeMar 11, 2024Big-stake noticeSEC
4 · Change in ownershipMar 6, 2024Insider tradeSEC
4 · Change in ownershipMar 6, 2024Insider tradeSEC
8-K · Current reportFeb 29, 2024ResultsSEC
424B5 · ProspectusFeb 29, 2024Offer documentSEC
SC 13G · Big-stake noticeFeb 27, 2024Big-stake noticeSEC
4 · Change in ownershipJan 29, 2024Insider tradeSEC
4 · Change in ownershipJan 24, 2024Insider tradeSEC
4 · Change in ownershipJan 24, 2024Insider tradeSEC
4 · Change in ownershipJan 24, 2024Insider tradeSEC
4 · Change in ownershipJan 24, 2024Insider tradeSEC
4 · Change in ownershipJan 24, 2024Insider tradeSEC
4 · Change in ownershipJan 24, 2024Insider tradeSEC
4 · Change in ownershipJan 24, 2024Insider tradeSEC
4 · Change in ownershipJan 24, 2024Insider tradeSEC
8-K · Current reportDec 11, 2023Current reportSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportAug 14, 2023ResultsSEC

This page holds 200 of 1,001 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Achieve Life Sciences, Inc.’s releases · as of Jun 30, 2025

Common shares
110,034,457
Fully diluted
110,034,457

Fully diluted

LineShares
Common shares110,034,457

Warrants and options

Lot
Warrants · US$3.00 · expire about Jun 2030

Share count over time

CountShares
Nov 22, 2026110,034,457

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Frazier Life Sciences Management, L.P.7.61M6.9%US$61.6MSep 30, 2026
Tpg Gp A, LLC6.88M6.3%US$55.6MSep 30, 2026
Logos Global Management LP5.95M5.4%US$48.1MSep 30, 2026
venBio Partners LLC5.91M5.4%US$47.9MSep 30, 2026
Venrock Adviser, LLC5.5M5.0%US$44.5MSep 30, 2026
BlackRock5.49M5.0%US$44.4MSep 30, 2026
Paradigm Biocapital Advisors LP4.95M4.5%US$40.1MSep 30, 2026
Vanguard4.89M4.4%US$39.6MSep 30, 2026
Propel Bio Management, LLC3.86M3.5%US$31.3MSep 30, 2026
JPMorgan3.79M3.4%US$29.1MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Marshall Wace, LLP3.77M3.4%US$30.5MSep 30, 2026
State Street3.72M3.4%US$30.1MSep 30, 2026
Eventide Asset Management, LLC3.57M3.2%US$28.9MSep 30, 2026
Franklin Templeton3.13M2.8%US$21.9MSep 30, 2026
Vivo Capital, LLC2.75M2.5%US$22.3MSep 30, 2026
Janus Henderson2.75M2.5%US$22.3MSep 30, 2026
Orbimed Advisors LLC2.34M2.1%US$19MSep 30, 2026
Geode Capital2.16M2.0%US$17.5MSep 30, 2026
Boxer Capital Management, LLC2.15M2.0%US$17.4MSep 30, 2026
Wellington1.65M1.5%US$13.3MSep 30, 2026
Alyeska Investment Group, L.P.976K0.89%US$7.89MSep 30, 2026
LPL Financial LLC974K0.88%US$7.88MSep 30, 2026
Simplify Asset Management Inc.932K0.85%US$7.54MSep 30, 2026
BNY754K0.69%US$6.1MSep 30, 2026
Northern Trust743K0.68%US$6.01MSep 30, 2026
Spruce Street Capital LP737K0.67%US$5.96MSep 30, 2026
Ameriprise731K0.66%US$5.92MSep 30, 2026
Raymond James Financial Inc583K0.53%US$4.72MSep 30, 2026
Mercer Global Advisors Inc551K0.50%US$4.45MSep 30, 2026
ADAR1 Capital Management, LLC508K0.46%US$4.11MSep 30, 2026
KVP Capital Advisors, LP462K0.42%US$3.74MSep 30, 2026
Adage Capital Partners Gp, L.L.C.460K0.42%US$3.72MSep 30, 2026
Caption Management, LLC429K0.39%US$3.47MSep 30, 2026
Blue Owl Capital Holdings LP413K0.38%US$3.34MSep 30, 2026
Point72 Asset Management, L.P.377K0.34%US$3.05MSep 30, 2026
Fidelity339K0.31%US$2.74MSep 30, 2026
Renaissance Technologies317K0.29%US$2.57MSep 30, 2026
UBS293K0.27%US$2.37MSep 30, 2026
Citadel275K0.25%US$2.22MSep 30, 2026
Invesco235K0.21%US$1.9MSep 30, 2026
Schwab232K0.21%US$1.88MSep 30, 2026
Bank of America213K0.19%US$1.72MSep 30, 2026
Morgan Stanley208K0.19%US$1.68MSep 30, 2026
Nuveen183K0.17%US$1.48MSep 30, 2026
Silverarc Capital Management, LLC159K0.14%US$1.29MSep 30, 2026
Goldman Sachs156K0.14%US$1.26MSep 30, 2026
Informed Momentum Co LLC147K0.13%US$1.19MSep 30, 2026
Hurricane Capital Advisors LLC138K0.13%US$1.11MSep 30, 2026
Cantor Fitzgerald, L. P.122K0.11%US$986KSep 30, 2026
Greenland Capital Management LP120K0.11%US$971KSep 30, 2026

This page holds 50 of 128 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund3.11M2.8%US$20.3MJun 30, 2026
Eventide Healthcare & Life Sciences Fund2.22M2.0%US$14.5MJun 30, 2026
iShares Russell 2000 ETF1.99M1.8%US$13MJun 30, 2026
Simplify Propel Opportunities ETF1.43M1.3%US$9.35MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1.35M1.2%US$8.81MJun 30, 2026
Franklin Biotechnology Discovery Fund1.1M1.00%US$7.03MJul 31, 2026
Vanguard Extended Market Index Fund957K0.87%US$6.25MJun 30, 2026
Fidelity Small Cap Index Fund852K0.77%US$5.47MJul 31, 2026
iShares Russell 2000 Growth ETF731K0.66%US$4.77MJun 30, 2026
Fidelity Extended Market Index Fund276K0.25%US$1.45MMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
iShares Micro-Cap ETF262K0.24%US$1.71MJun 30, 2026
Schwab Small-Cap Index Fund189K0.17%US$1.21MJul 31, 2026
Master Small Cap Index Series146K0.13%US$950KJun 30, 2026
Nuveen Small Cap Blend Index Fund103K0.09%US$664KJul 31, 2026
Fidelity Total Market Index Fund97,1740.09%US$509KMay 31, 2026
EQ/2000 Managed Volatility Portfolio84,1480.08%US$549KJun 30, 2026
Fidelity Series Total Market Index Fund80,1610.07%US$420KMay 31, 2026
Fidelity Small Cap Growth Index Fund72,9340.07%US$476KJun 30, 2026
Nuveen Equity Index Fund67,1940.06%US$431KJul 31, 2026
Virtus Biotech Clinical Trials Etf56,3080.05%US$361KJul 31, 2026
LVIP State Street Small-Cap Index Fund56,3000.05%US$368KJun 30, 2026
Fidelity ZERO Total Market Index Fund46,6420.04%US$299KJul 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares45,8650.04%US$294KJul 31, 2026
Schwab Total Stock Market Index Fund43,0000.04%US$276KJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund42,2350.04%US$276KJun 30, 2026
Small Cap Index Fund40,1600.04%US$262KJun 30, 2026
Fidelity Nasdaq Composite Index Fund37,7700.03%US$198KMay 31, 2026
Global X Russell 2000 ETF37,0280.03%US$238KJul 31, 2026
Vanguard Balanced Index Fund33,1050.03%US$216KJun 30, 2026
Fidelity ZERO Extended Market Index Fund30,5770.03%US$196KJul 31, 2026
ATM Small Cap Managed Volatility Portfolio28,1310.03%US$184KJun 30, 2026
MetLife Russell 2000 Index Portfolio26,0740.02%US$170KJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio25,5000.02%US$167KJun 30, 2026
Small Cap Core Fund24,2030.02%US$158KJun 30, 2026
Small-Cap Index Portfolio22,1140.02%US$144KJun 30, 2026
EQ/Small Company Index Portfolio19,0400.02%US$124KJun 30, 2026
EQ/AB Small Cap Growth Portfolio19,0400.02%US$124KJun 30, 2026
1290 VT Micro Cap Portfolio17,4630.02%US$114KJun 30, 2026
NVIT Small Cap Index Fund17,1670.02%US$112KJun 30, 2026
Small Cap Index Trust16,0880.01%US$105KJun 30, 2026
iShares Russell Small/Mid-Cap Index Fund13,6270.01%US$87,485Jul 31, 2026
Biotechnology Ultrasector Profund12,8700.01%US$82,625Jul 31, 2026
Fidelity Flex Small Cap Index Fund12,4860.01%US$80,160Jul 31, 2026
DWS Small Cap Index VIP12,2190.01%US$79,790Jun 30, 2026
T. Rowe Price Small-Cap Index Fund11,8730.01%US$77,531Jun 30, 2026
EQ/Morgan Stanley Small Cap Growth Portfolio11,7320.01%US$76,610Jun 30, 2026
BlackRock Small Cap Index V.I. Fund10,451<0.01%US$68,245Jun 30, 2026
Voya RussellTM Small Cap Index Portfolio9,509<0.01%US$62,094Jun 30, 2026
SA Small Cap Index Portfolio9,115<0.01%US$58,518Jul 31, 2026
Victory Extended Market Index Fund8,529<0.01%US$54,756Jul 31, 2026

This page holds 50 of 78 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Stewart Richard Alistair
Director
Sale20,626USD 8.49US$175KAug 19, 2026

Big stakes

StakeStakeSharesDateFiling
Tpg Gp A, LLC12.60%13.8MApr 17, 2025Schedule 13D
venBio Global Strategic Fund V, L.P.9.99%10.7MApr 15, 2026Schedule 13D
Paradigm Biocapital Advisors LP9.20%9.9MApr 17, 2026Schedule 13G
Logos Global Management LP8.60%9.7MSep 30, 2026Schedule 13G
Franklin Resources Inc8.30%8.88MJun 30, 2026Schedule 13G
Frazier Life Sciences Public Fund, L.P.6.50%6.63MApr 17, 2026Schedule 13G
Janus Henderson Group PLC5.40%5.5MJun 30, 2026Schedule 13G
Venrock Healthcare Capital Partners III, L.P.5.20%5.5MSep 30, 2026Schedule 13G
BlackRock, Inc.5.10%5.27MJun 30, 2026Schedule 13G
Vivo Opportunity, LLC5.00%5.31MJul 6, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jeffrey Farrow
Other companies: Tarsus Pharmaceuticals, Inc. (See Remarks · Since at least Apr 24, 2023); Lisata Therapeutics, Inc. (Director · Since Oct 13, 2026 · Appointed, no departure found); Global Blood Therapeutics Inc (Chief Financial Officer · Apr 4, 2016 – Oct 5, 2022 · Past); ZS Pharma Inc (Chief Financial Officer · Jul 8, 2015 – Dec 17, 2015 · Past); Hyperion Therapeutics Inc (CFO · Jul 25, 2012 – May 7, 2015 · Past); Renovis Inc (V.P., Finance and CAO · Jul 1, 2007 – May 2, 2008 · Past)
Director · Since at least May 29, 2026
Bridget Martell
Other companies: Delcath Systems, Inc. (Director · Since at least May 23, 2024); Aligos Therapeutics, Inc. (Director · Since at least Nov 16, 2021); Ayala Pharmaceuticals Inc (Director · Oct 18, 2023 – Oct 18, 2023 · Past); POINT Biopharma Global Inc (Director · Jun 12, 2023 – Jun 13, 2023 · Past); Kura Oncology, Inc. (Acting Chief Medical Officer · Feb 10, 2020 – Aug 24, 2020 · Past)
Director · Since at least Mar 15, 2021
Donald Joseph
Other companies: Acer Therapeutics Inc (See Remarks · Apr 16, 2018 – Nov 17, 2023 · Past); Humanigen Inc (Chief Legal Officer · Jul 30, 2013 – Feb 16, 2015 · Past); Renovis Inc (SVP, Gen. Counsel & Secretary · May 16, 2006 – Jan 3, 2007 · Past); Abgenix Inc (Senior VP, Gen. Counsel & Sec. · Apr 1, 2006 – Apr 1, 2006 · Past)
Director · Aug 1, 2017 – May 31, 2022 · Past
H Stewart Parker
Other companies: Codexis, Inc. (Director · Since at least Dec 16, 2022); Sangamo Therapeutics, Inc. (Director · Since at least Jun 17, 2014); Impel Neuropharma Inc (Director · Apr 22, 2021 – Jul 11, 2021 · Past); Armata Pharmaceuticals, Inc. (Director · Jun 12, 2006 – May 22, 2019 · Past)
Director · Mar 23, 2010 – May 12, 2020 · Past
Jay M. Moyes
Other companies: SiNtx Technologies, Inc. (Audit Committee Chair · Since at least Apr 3, 2025); Puma Biotechnology Inc (Director · Since at least Jun 14, 2022); BioCardia, Inc. (Director · Since at least Jun 10, 2022); Sera Prognostics, Inc. (Chief Financial Officer · Mar 6, 2023 – Jun 7, 2023 · Past)
Director · May 31, 2022 – May 31, 2022 · Past
Lucian Iancovici
Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Rallybio Corporation (Board Member · Since at least Jul 29, 2021); CeriBell, Inc. (Director · Oct 10, 2024 – Oct 10, 2024 · Past)
Chairman of the Board of Directors · Since at least Apr 17, 2026
Mark Oki
Other companies: Aytu BioPharma, Inc. (Chief Financial Officer · Jan 17, 2022 – Aug 11, 2023 · Past); VIVUS Inc (Chief Financial Officer & CAO · Oct 19, 2015 – Jan 29, 2020 · Past); Alexza Pharmaceuticals Inc (Former SVP, CFO, Secretary · May 18, 2010 – Oct 16, 2015 · Past)
Chief Financial Officer · Since at least Dec 5, 2024
Stuart Duty
Other companies: Foghorn Therapeutics Inc. (Director · Since at least May 1, 2025); Milestone Pharmaceuticals Inc. (Independent Non-Executive Director · Since at least Jul 15, 2024); EyePoint, Inc. (Board Member · Since at least Oct 16, 2023)
Director · Since at least Mar 29, 2023
Christopher Martin
Other companies: Oruka Therapeutics, Inc. (Director · Since at least Dec 11, 2025); Edgewise Therapeutics, Inc. (Director · Since at least Nov 19, 2025)
Director · Since at least May 11, 2026
Erik Atkisson
Other companies: Rain Oncology Inc (General Counsel and CCO · Mar 2, 2023 – Jan 26, 2024 · Past); Eiger Biopharmaceuticals Inc (GC & Chief Compliance Officer · Sep 22, 2021 – Jan 26, 2023 · Past)
Chief Legal Officer · Since at least Oct 20, 2025
All 32 people
PersonSeat
George W Dunbar Jr
Other companies: Capricor Therapeutics, Inc. (Director · Since at least Nov 20, 2013); Vericel Corporation (Director · Jul 17, 2006 – Mar 11, 2010 · Past)
Director · May 9, 2006 – May 10, 2007 · Past
John Bencich
Other companies: AEON Biopharma, Inc. (Chief Financial Officer - · Since at least Apr 1, 2026); Trubion Pharmaceuticals Inc (V.P. and CFO · Nov 16, 2009 – Oct 28, 2010 · Past)
CEO, Director · Aug 11, 2014 – Aug 16, 2024 · Past
Andrew D. Goldberg
Other companies: Tarsus Pharmaceuticals, Inc. (Director · Since at least Dec 15, 2023)
CEO and President, Director · Since at least Apr 18, 2026
Cameron William Lawrence
Other companies: GNC Holdings Inc (SVP Finance, CAO · Apr 15, 2019 – Mar 25, 2020 · Past)
Principal Accounting Officer · Feb 24, 2010 – May 8, 2012 · Past
Dwight Winstead
Other companies: CareFusion Corp (Chief Operating Officer · Jul 28, 2009 – Dec 7, 2010 · Past)
Director · May 9, 2006 – May 13, 2010 · Past
Reid Waldman
Other companies: Veradermics, Incorporated (Chief Executive Officer, Director · Since at least Feb 3, 2026)
Director · Since at least May 29, 2026
Thomas Braxton King
Other companies: TFF Pharmaceuticals Inc (Director · Dec 11, 2023 – Jul 3, 2024 · Past)
Director · Since at least Jan 22, 2024
Aaron E. RoystonDirector · Since at least Apr 16, 2026
Benjamin HalladayChief Financial Officer · Since Oct 5, 2026
Cindy JacobsPresident & CMO · Since at least Aug 21, 2008
Craig DonnellyChief Operations Officer · Since at least Jan 28, 2025
Jaime XinosChief Commercial Officer · Since at least Oct 15, 2024
Kaitlyn TusonSenior Vice President, Marketing and Communications · Since at least Oct 7, 2026
Kristen B SlaouiDirector · Since at least Jan 6, 2025
Mark RubinsteinChief Medical Officer · Since at least Jan 28, 2025
Martin A MattinglyDirector · May 11, 2021 – May 31, 2022 · Past
Nancy PhelanDirector · Since at least Mar 11, 2025
Nicole JonesVP, Strategic Communications and Stakeholder Relations · Since at least Nov 2, 2026
Richard StewartDirector · Since at least Jan 22, 2024
Scott Daniel CormackDirector · Aug 21, 2008 – May 12, 2020 · Past
Thomas SelligDirector · Since at least Mar 29, 2023
Tom SelligDirector · Since at least Apr 15, 2026

Open People

Log in to ask 6ix AI your own questions about Achieve Life Sciences, Inc.